838-P: Changes in Clinical Measures in U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Who Received Once-Weekly (OW) Semaglutide

Introduction and Objective: To assess changes in clinical measures in US adults with T2D and CKD treated with OW semaglutide. Methods: Adults with T2D and CKD who initiated OW semaglutide between Jan 1, 2019 and Jun 30, 2023 were selected from Optum’s de-identified Clinformatics® Data Mart Database. Clinical measures were compared before vs. during OW semaglutide treatment. Changes were described at Month 12, and trajectories were analyzed with mixed models in the overall cohort and subgroups: those 1) ineligible for sodium-glucose cotransporter-2 inhibitor (SGLT2i) due to advanced CKD stages, 2) for whom SGLT2is were suboptimal indicated by treatment switch or augmentation with OW semaglutide after SGLT2i use, and 3) with stage IV CKD or kidney failure. Results: Out of 49,683 patients, 67.6% were aged 65 or older and 56.7% were female. After OW semaglutide treatment, there was a decline in HbA1c (12-month mean change [95% confidence interval]: -1.2% [-1.3%, -1.2%]), increase in estimated glomerular filtration rate (1.6 mL/min/1.73 m2 [1.2, 2.0]), decline in body weight (-6.0 kg [-6.7, -5.4]), and decline in systolic blood pressure (SBP; -2.9 mmHg [-4.1, -1.7]). Similar trends were observed in all subgroups. Conclusion: Real-world patients with T2D and CKD treated with OW semaglutide had improved glycemic control and kidney function and reduced body weight and SBP. Disclosure J. Amamoo: Employee; Novo Nordisk. Y. Wang: Other Relationship; Analysis Group, Inc. H. Liu: Employee; Analysis Group, Inc. M. Sundar: Consultant; Novo Nordisk. Y. Song: Research Support; Novo Nordisk. L. Xie: None. S.J. Mehanna: None. J. Noone: Employee; Novo Nordisk. C. Swift: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. M.R. Weir: Advisory Panel; AstraZeneca, Bayer Pharmaceuticals, Inc, Novo Nordisk, Corcept Therapeutics, Vifor Pharma. Consultant; Intercept Pharmaceuticals, Inc.